BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Le BL, Andreoletti G, Oskotsky T, Vallejo-Gracia A, Rosales R, Yu K, Kosti I, Leon KE, Bunis DG, Li C, Kumar GR, White KM, García-Sastre A, Ott M, Sirota M. Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19. Sci Rep 2021;11:12310. [PMID: 34112877 DOI: 10.1038/s41598-021-91625-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Loas G, Le Corre P. Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection. Pharmaceuticals (Basel) 2021;14:691. [PMID: 34358117 DOI: 10.3390/ph14070691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Alsulaimany FA, Zabermawi NMO, Almukadi H, Parambath SV, Shetty PJ, Vaidyanathan V, Elango R, Babanaganapalli B, Shaik NA. Transcriptome-Based Molecular Networks Uncovered Interplay Between Druggable Genes of CD8+ T Cells and Changes in Immune Cell Landscape in Patients With Pulmonary Tuberculosis. Front Med (Lausanne) 2021;8:812857. [PMID: 35198572 DOI: 10.3389/fmed.2021.812857] [Reference Citation Analysis]
3 Kruse M, Altattan B, Laux EM, Grasse N, Heinig L, Möser C, Smith DM, Hölzel R. Characterization of binding interactions of SARS-CoV-2 spike protein and DNA-peptide nanostructures. Sci Rep 2022;12:12828. [PMID: 35896714 DOI: 10.1038/s41598-022-16914-9] [Reference Citation Analysis]
4 Lam MTY, Duttke SH, Odish MF, Le HD, Hansen EA, Nguyen CT, Trescott S, Kim R, Deota S, Chang MW, Patel A, Hepokoski M, Alotaibi M, Rolfsen M, Perofsky K, Warden AS, Foley J, Ramirez SI, Dan JM, Abbott RK, Crotty S, Crotty Alexander LE, Malhotra A, Panda S, Benner CW, Coufal NG. Profiling Transcription Initiation in Peripheral Leukocytes Reveals Severity-Associated Cis-Regulatory Elements in Critical COVID-19. bioRxiv 2021:2021. [PMID: 34462742 DOI: 10.1101/2021.08.24.457187] [Reference Citation Analysis]
5 Serra A, Fratello M, Federico A, Ojha R, Provenzani R, Tasnadi E, Cattelani L, Del Giudice G, Kinaret PAS, Saarimäki LA, Pavel A, Kuivanen S, Cerullo V, Vapalahti O, Horvath P, Lieto AD, Yli-Kauhaluoma J, Balistreri G, Greco D. Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation. Brief Bioinform 2021:bbab507. [PMID: 34962256 DOI: 10.1093/bib/bbab507] [Reference Citation Analysis]
6 Hassan J, Haigh C, Ahmed T, Uddin MJ, Das DB. Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges. Pharmaceutics 2022;14:1066. [DOI: 10.3390/pharmaceutics14051066] [Reference Citation Analysis]
7 Imami AS, McCullumsmith RE, O'Donovan SM. Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example. Transl Psychiatry 2021;11:591. [PMID: 34785660 DOI: 10.1038/s41398-021-01724-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lu L, Qin J, Chen J, Wu H, Zhao Q, Miyano S, Zhang Y, Yu H, Li C. DDIT: An Online Predictor for Multiple Clinical Phenotypic Drug-Disease Associations. Front Pharmacol 2022;12:772026. [DOI: 10.3389/fphar.2021.772026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]